PE anti-mouse CD3 Antibody

Pricing & Availability
Clone
17A2 (See other available formats)
Regulatory Status
RUO
Other Names
T cell antigen receptor complex, T3
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
17A2_PE_021606
C57BL/6 mouse splenocytes stained with 17A2 PE
  • 17A2_PE_021606
    C57BL/6 mouse splenocytes stained with 17A2 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
100205 50 µg £42
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100206 200 µg £98
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
γδTCR-positive T-T hybridoma D1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported application (for relevant formats) include: spatial biology (IBEX)1,2.

Application References

(PubMed link indicates BioLegend citation)
  1. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  2. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Zuchtriegel G, et al. 2016. PLoS Biol. 14: 1002459. PubMed
  2. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  3. Hiyoshi H, et al. 2022. Cell Host Microbe. 30:163. PubMed
  4. Chan WY, et al. 2022. Infect Immun. 90:e0084618a. PubMed
  5. Wang D, et al. 2022. Cell Rep. 39:110587. PubMed
  6. Mirchandani AS, et al. 2022. Nat Immunol. 23:927. PubMed
  7. Yang K, et al. 2022. Sci Immunol. 7:eabn2888. PubMed
  8. McAlpine CS, et al. 2022. J Exp Med. 219: . PubMed
  9. TaSli PN, et al. 2022. J Food Biochem. 46:e14393. PubMed
  10. Shen Z, et al. 2022. EBioMedicine. 85:104285. PubMed
  11. Deng P, et al. 2022. J Clin Invest. 132: . PubMed
  12. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  13. Domingos-Pereira S, et al. 2022. Int J Mol Sci. 24: . PubMed
  14. Giannou AD, et al. 2023. Immunity. 56:125. PubMed
  15. Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed
  16. Meacham CE, et al. 2022. Nat Cell Biol. 24:697. PubMed
  17. Zhao L, et al. 2022. Oncogene. 41:4200. PubMed
  18. Guo D, et al. 2023. Cell Biosci. 13:51. PubMed
  19. Fan NW, et al. 2023. FASEB J. 37:e22855. PubMed
  20. Zhang X, et al. 2023. Front Immunol. 14:1116749. PubMed
  21. Sun JY, et al. 2023. Sci Adv. 9:eade4110. PubMed
  22. Shi Y, et al. 2023. Nat Commun. 14:1884. PubMed
  23. Fiedler T, et al. 2023. J Neuroinflammation. 20:100. PubMed
  24. Li Y, et al. 2023. Front Cell Infect Microbiol. 13:1117230. PubMed
  25. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  26. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  27. Milighetti M, et al. 2023. iScience. 26:106937. PubMed
  28. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  29. Correa S, et al. 2020. ACS Nano. 14:2224. PubMed
  30. Gonalves S, et al. 2021. Cell Reports. 34(11):108860. PubMed
  31. Reboldi A, et al. 2016. Sci Transl Med. 352: aaf4822. PubMed
  32. Gazit R, et al. 2014. J Exp Med. 211:1315. PubMed
  33. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  34. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  35. Jong RM, et al. 2022. J Immunol. 208:407. PubMed
  36. Baryawno N et al. 2019. Cell. 177(7):1915-1932 . PubMed
  37. Shen S, et al. 2018. Pain Med. 19:686. PubMed
  38. Ushijima M, et al. 2018. Front Immunol. 9:243. PubMed
  39. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  40. Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
  41. Kunimura K, et al. 2020. Cell Reports. 29(9):2823-2834.e7.. PubMed
  42. Bedi B, et al. 2012. Proc Natl Acad Sci U S A. 109:275. PubMed
  43. Liang W, et al. 2020. Nat Commun. 4.563888889. PubMed
  44. Shu T, et al. 2022. Eur Respir J. Online ahead of print. PubMed
  45. Al-Rifai R, et al. 2022. Nat Commun. 13:6592. PubMed
  46. Jazowiecka-Rakus J, et al. 2021. Cancers (Basel). 13:. PubMed
  47. Lutzmann M, et al. 2019. Cell Rep. 28:2851. PubMed
  48. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  49. Lechner AJ et al. 2017. Cell stem cell. 21(1):120-134 . PubMed
  50. Schmidt D, et al. 2016. PLoS One. 11: 0159059. PubMed
  51. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  52. Kuang Z, et al. 2020. Antib Ther. 3:227. PubMed
  53. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  54. Mathur S, et al. 2021. JCI Insight. 6:. PubMed
  55. Ohyagi M, et al. 2021. Nat Commun. 12:7344. PubMed
  56. Yan X, et al. 2022. Int J Biol Sci. 18:585. PubMed
  57. Helm M, et al. 2022. Life (Basel). 12:. PubMed
  58. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  59. Ma C, et al. 2018. Science. 360:eaan5931. PubMed
  60. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  61. Vannini N, et al. 2019. Cell Stem Cell. 24:405. PubMed
  62. Biram A, et al. 2020. Cell Rep. 30:1910. PubMed
  63. Delgado‐Benito V et al. 2018. Molecular cell. 72(4):636-649 . PubMed
  64. Mariani SA, et al. 2019. Immunity. 50:1439. PubMed
  65. Stutchfield B, et al. 2015. Gastroenterology. 149: 1896-1909.e14. PubMed
  66. Koren N, et al. 2021. Cell Host Microbe. 29(2):197-209.e5. PubMed
  67. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  68. Zhou Y, et al. 2022. Nat Commun. 13:2906. PubMed
  69. Stivala S, et al. 2019. J Clin Invest. 130:1596. PubMed
  70. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  71. Wu J, et al. 2020. Immunity. 53:115. PubMed
  72. McAlpine CS, et al. 2021. Nature. 595:701. PubMed
  73. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  74. Goldman E, et al. 2021. Cells. 10:. PubMed
  75. Cassidy BR, et al. 2020. J Neuroinflammation. 17:259. PubMed
  76. Domingos-Pereira S, et al. 2019. Cancer Immunol Res. 7:621. PubMed
  77. Lin H, et al. 2019. Infect Immun. 87:e00055-19. PubMed
  78. Pedraza–Zamora CP, et al. 2017. Parasite Immunol. 39:4. PubMed
  79. Chen Y, et al. 2015. PLoS One. 10: 0135217. PubMed
  80. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  81. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  82. Marinescu CI, et al. 2021. Stem Cell Res Ther. 12:319. PubMed
  83. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  84. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  85. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  86. Hu J, et al. 2022. J Neuroinflammation. 19:71. PubMed
  87. Doonan J, et al. 2019. Nat Commun. 10:1554. PubMed
  88. Halpern KB, et al. 2018. Nat Biotechnol. 36:962. PubMed
  89. Deng M, et al. 2020. Nat Commun. 11:2193. PubMed
  90. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  91. Fang E, et al. 2022. MedComm (2020). 3:e117. PubMed
  92. Harnett MM, et al. 2022. Front Immunol. 13:953053. PubMed
  93. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  94. O'Connor T, et al. 2020. Cancer Cell. 36(3):250-267. PubMed
  95. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  96. Chauveau A, et al. 2020. Immunity. 52:794. PubMed
  97. Mishra BB, et al. 2017. Nat Microbiol. 2:17072. PubMed
  98. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  99. Pedraza-Zamora C, et al. 2017. Parasite Immunol. 10.1111/pim.12420. PubMed
  100. Lewandowski JP, et al. 2020. Genome Biol. 1.039583333. PubMed
  101. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  102. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  103. Cho K, et al. 2021. iScience. 24:103117. PubMed
  104. Zhou Z, et al. 2022. Infect Immun. 90:e0045321. PubMed
  105. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
  106. Tomala J, et al. 2020. Methods Mol Biol. 2111:101. PubMed
  107. Nikolos F, et al. 2022. Nat Commun. 13:1487. PubMed
  108. Xiang W, et al. 2018. Nat Commun. 9:2574. PubMed
  109. Rozanski C, et al. 2015. J Immunol. 194:4717. PubMed
  110. Sanmarco LM, et al. 2021. Nature. 590:473. PubMed
  111. Zou D, et al. 2020. EBioMedicine. 52:102652. PubMed
  112. Fang H, et al. 2020. Nat Commun. 4.661805556. PubMed
  113. Tummers B, et al. 2020. Immunity. 52(6):994-1006.e8. PubMed
  114. Gamrekelashvili J, et al. 2021. Bio Protoc. 11:e4007. PubMed
  115. Feng Y, et al. 2022. J Nanobiotechnology. 20:193. PubMed
  116. Sun J et al. 2018. Cell stem cell. 23(3):355-369 . PubMed
  117. Huang L, et al. 2018. Exp Neurol. 300:41. PubMed
  118. Ding Y, et al. 2020. Evid Based Complement Alternat Med. 2020:9521073. PubMed
  119. Zhang T, et al. 2020. Cell. 180(6):1115-1129. PubMed
  120. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  121. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  122. Yamamura K, et al. 2017. Nat Commun. 8:13946. PubMed
  123. Hsieh Y, et al. 2014. Infect Immun . 82:2087. PubMed
  124. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  125. Olson B, et al. 2021. Brain Behav Immun. 97:102. PubMed
  126. Winchell CG, et al. 2020. Front Immunol. 1.077083333. PubMed
  127. Chan WY, et al. 2019. Infect Immun. 87:. PubMed
  128. Schneider A, et al. 2014. J Leukoc Biol. 96:857. PubMed
  129. Zhang MS, et al. 2022. Nat Commun. 13:954. PubMed
  130. Jazowiecka-Rakus J, et al. 2020. Mol Ther Oncolytics. 18:335. PubMed
  131. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  132. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  133. Zhou T, et al. 2021. Bioact Mater. 0.734027778. PubMed
  134. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  135. Zhou H, et al. 2021. Cell Death Discov. 7:332. PubMed
  136. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  137. Lu C, et al. 2020. Cancer Cell. 39(1):96-108.e6. PubMed
  138. Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed
  139. Uluçkan ö, et al. 2020. Cell Reports. 29(4):844-859.e3.. PubMed
  140. Maulhardt HA, et al. 2020. Invest New Drugs. 1618:38. PubMed
  141. Yu H, et al. 2015. PLoS One. 10: 0143001. PubMed
  142. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  143. Fathman J, et al. 2010. Proc Natl Acad Sci U S A. 107:3663. PubMed
  144. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  145. Gundra UM, et al. 2017. Nat Immunol. 1.195833333. PubMed
  146. Vannini N, et al. 2016. Nat Commun. 7:13125. PubMed
  147. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  148. Das A, et al. 2020. J Bone Miner Res. 36:199. PubMed
  149. Gawish R, et al. 2022. Elife. 11:. PubMed
  150. Crowe J, et al. 2020. PLoS Pathog. 16:e1008391. PubMed
  151. Zeng F, et al. 2021. J Invest Dermatol. 596:141. PubMed
  152. Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed
  153. Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed
  154. Hayashi K, et al. 2020. Nat Commun. 4.832638889. PubMed
  155. He C, et al. 2021. Immunol Cell Biol. 99:611. PubMed
  156. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  157. Zuo S, et al. 2021. EBioMedicine. 64:103240. PubMed
RRID
AB_312662 (BioLegend Cat. No. 100205)
AB_312662 (BioLegend Cat. No. 100206)

Antigen Details

Structure
Ig superfamily, CD3/TCR, 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
Antigen recognition, TCR signal transduction, T cell activation
Ligand/Receptor
Peptide antigen/MHC-complex
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12502 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD3 Reagents Request Custom Conjugation
Description Clone Applications
FITC anti-mouse CD3 17A2 FC
PE anti-mouse CD3 17A2 FC
Purified anti-mouse CD3 17A2 FC,IHC-F,IP,ICC
Alexa Fluor® 647 anti-mouse CD3 17A2 FC,IHC-F,3D IHC,SB
Alexa Fluor® 488 anti-mouse CD3 17A2 FC,IHC-F,3D IHC
Pacific Blue™ anti-mouse CD3 17A2 FC
Alexa Fluor® 700 anti-mouse CD3 17A2 FC
PerCP/Cyanine5.5 anti-mouse CD3 17A2 FC
PE/Cyanine7 anti-mouse CD3 17A2 FC
APC/Cyanine7 anti-mouse CD3 17A2 FC
Brilliant Violet 421™ anti-mouse CD3 17A2 FC,ICC
Brilliant Violet 570™ anti-mouse CD3 17A2 FC
Brilliant Violet 650™ anti-mouse CD3 17A2 FC
Brilliant Violet 785™ anti-mouse CD3 17A2 FC
Brilliant Violet 510™ anti-mouse CD3 17A2 FC
APC anti-mouse CD3 17A2 FC
Ultra-LEAF™ Purified anti-mouse CD3 17A2 FC,IHC-F,IP,ICC
Brilliant Violet 605™ anti-mouse CD3 17A2 FC
Alexa Fluor® 594 anti-mouse CD3 17A2 IHC-F,FC,3D IHC,SB
Brilliant Violet 711™ anti-mouse CD3 17A2 FC
Biotin anti-mouse CD3 17A2 FC,IHC-F
PE/Dazzle™ 594 anti-mouse CD3 17A2 FC
APC/Fire™ 750 anti-mouse CD3 17A2 FC
Brilliant Violet 750™ anti-mouse CD3 17A2 FC
TotalSeq™-A0182 anti-mouse CD3 17A2 PG
TotalSeq™-B0182 anti-mouse CD3 17A2 PG
Spark Blue™ 550 anti-mouse CD3 17A2 FC
Spark NIR™ 685 anti-mouse CD3 17A2 FC
TotalSeq™-C0182 anti-mouse CD3 17A2 PG
APC/Fire™ 810 anti-mouse CD3 17A2 FC
PE/Fire™ 640 anti-mouse CD3 17A2 FC
Spark YG™ 570 anti-mouse CD3 17A2 IHC-F
PE/Fire™ 700 anti-mouse CD3 17A2 FC
PE/Cyanine5 anti-mouse CD3 17A2 FC
Spark Blue™ 574 anti-mouse CD3 Antibody 17A2 FC
Spark Violet™ 423 anti-mouse CD3 17A2 FC
PE/Fire™ 810 anti-mouse CD3 17A2 FC
Spark Red™ 718 anti-mouse CD3 17A2 FC
Spark UV™ 387 anti-mouse CD3 17A2 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account